- Report
- July 2023
- 220 Pages
From €3113EUR$3,450USD£2,705GBP
- Report
- July 2023
- 253 Pages
Europe
From €3113EUR$3,450USD£2,705GBP
- Report
- May 2023
- 156 Pages
Global
From €4016EUR$4,450USD£3,489GBP
- Report
- February 2023
- 217 Pages
Global
From €4016EUR$4,450USD£3,489GBP
- Report
- March 2025
- 150 Pages
Global
From €4377EUR$4,850USD£3,803GBP
- Report
- March 2025
- 150 Pages
Global
From €4377EUR$4,850USD£3,803GBP
- Report
- February 2025
- 150 Pages
Global
From €4377EUR$4,850USD£3,803GBP
- Report
- November 2024
- 150 Pages
Global
From €4377EUR$4,850USD£3,803GBP
- Report
- December 2024
- 150 Pages
Global
From €3030EUR$3,358USD£2,632GBP
€3565EUR$3,950USD£3,097GBP
- Report
- January 2025
- 97 Pages
Global
From €3500EUR$4,155USD£3,147GBP
- Report
- March 2025
- 67 Pages
Global
From €1760EUR$1,950USD£1,529GBP
- Report
- January 2025
- 127 Pages
Global
From €2662EUR$2,950USD£2,313GBP
- Report
- May 2024
- 119 Pages
Global
From €1760EUR$1,950USD£1,529GBP
- Report
- December 2023
- 76 Pages
Global
From €7215EUR$7,995USD£6,269GBP
- Report
- December 2022
- 110 Pages
Global
From €1760EUR$1,950USD£1,529GBP
- Report
- August 2023
- 1300 Pages
Global
From €8032EUR$8,900USD£6,978GBP
- Report
- August 2023
- 300 Pages
Asia Pacific
From €4422EUR$4,900USD£3,842GBP
- Report
- August 2023
- 300 Pages
Europe
From €4422EUR$4,900USD£3,842GBP
- Report
- August 2023
- 300 Pages
Middle East, Africa
From €4422EUR$4,900USD£3,842GBP
- Report
- August 2023
- 300 Pages
Latin America
From €4422EUR$4,900USD£3,842GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more